Soleno Therapeutics Inc SLNO 深 滬
等待開盤 01-29 09:30:00 美东时间
41.60
-1.560
-3.61%
華盛通- 最 高43.31
- 今 開43.03
- 成交量 120.36万股
- 最 低 41.53
- 昨 收 43.16
- 總市值 21.94亿
- 52周最高 90.3199
- 市盈率 靜 --
- 換手率 2.28%
- 52周最低 39.43
- 委 比 68.60%
- 總股本 5274.69万
- 歷史最高 90.3199
- 量 比 1.04
- 振 幅 4.12%
- 歷史最低 1.81
- 每 手 1
- 風險率 14.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Soleno Therapeutics Updates Executive Compensation and Severance Plans
Soleno Therapeutics ( ($SLNO) ) just unveiled an announcement. On January 21, 2...
01-24 06:45
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
HC Wainwright & Co. Maintains Buy on Soleno Therapeutics, Raises Price Target to $120
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Soleno Therapeutics (NASDAQ:SLNO) with a Buy and raises the price target from $110 to $120.
01-20 19:48
Soleno Therapeutics Announces Peer-Reviewed JCEM Publication Highlighting VYKAT XR Withdrawal Period Study In Prader-Willi Syndrome
Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a publication in the peer-reviewed Journal of Clinical
01-05 21:17
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism
Soleno Therapeutics announced the publication of a study in the *Journal of Clinical Endocrinology and Metabolism* detailing a 16-week randomized withdrawal study of VYKAT™ XR (diazoxide choline extended-release tablets) for treating hyperphagia in Prader-Willi syndrome (PWS). The study, part of a Phase 3 clinical program, demonstrated that discontinuing VYKAT XR led to significant worsening of hyperphagia compared to continued treatment. VYKAT X...
01-05 13:00
Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise
Rhythm Pharma rises after early Prader-Willi trial data show reduced hunger and BMI, supporting plans for a Phase 3 study of setmelanotide.
2025-12-12 02:17
Soleno Therapeutics Announces the Passing of Board Member William G. Harris
Soleno Therapeutics announce the passing of Bill Harris, a valued Board member and Audit Committee Chairman since 2014. Harris, known for his integrity and expertise, had a prominent career in biopharmaceutical finance. Andrew Sinclair, a long-serving Board member, will assume the Audit Committee Chair position. Soleno focuses on rare disease therapeutics, with its FDA-approved VYKAT™ XR for Prader-Willi syndrome hyperphagia.
2025-12-03 21:05
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
Wolfe Research Initiates Coverage On Soleno Therapeutics with Outperform Rating, Announces Price Target of $75
Wolfe Research analyst Kalpit Patel initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Outperform rating and announces Price Target of $75.
2025-11-19 00:46
Soleno Therapeutics Unveils $100 Million Buyback Citing 'Underappreciated' Future
Soleno Therapeutics (SLNO) approved $100M share repurchase program & entered ASR agreement with Jefferies LLC to buy back its stock.
2025-11-11 23:22
